Research & Literature

Antinuclear Antibody-Negative Lupus Nephritis with Full House Nephropathy: A Case Report and Review of the Literature.

Simmons SC, Smith ML, Chang-Miller A, Keddis MT

American journal of nephrology 2015; (42(6)):451-9 doi:10.1159/000443747.

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study.

Tselios K, Gladman DD, Su J, Urowitz MB

Arthritis care & research 2016; (68(10)):1497-504 doi:10.1002/acr.22857.

Con: Cyclophosphamide for the treatment of lupus nephritis.

Mok CC

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(7)):1053-7 doi:10.1093/ndt/gfw068.

Pro: Cyclophosphamide in lupus nephritis.

Kallenberg CG

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(7)):1047-52 doi:10.1093/ndt/gfw069.

Comparison of Outcomes between Individuals with Pure and Mixed Lupus Nephritis: A Retrospective Study.

Ilori TO, Enofe N, Oommen A, et al.

PloS one 2016; (11(6)):e0157485 doi:10.1371/journal.pone.0157485.

Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis.

Mistry P, Kaplan MJ

Clinical immunology (Orlando, Fla.) 2017; (185()):59-73 doi:10.1016/j.clim.2016.08.010.

Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.

Mok CC

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(10)):1561-6 doi:10.1093/ndt/gfw289.

Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis.

Yung S, Chan TM

Clinical immunology (Orlando, Fla.) 2017; (185()):40-50 doi:10.1016/j.clim.2016.09.002.

Membranous Lupus Nephritis: The Same, But Different.

Ward F, Bargman JM

American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (68(6)):954-966 doi:10.1053/j.ajkd.2016.07.026.

Genetics of human lupus nephritis.

Iwamoto T, Niewold TB

Clinical immunology (Orlando, Fla.) 2017; (185()):32-39 doi:10.1016/j.clim.2016.09.012.

Anti-pentraxin 3 auto-antibodies might be protective in lupus nephritis: a large cohort study.

Yuan M, Tan Y, Pang Y, et al.

Renal failure 2017; (39(1)):465-473 doi:10.1080/0886022X.2017.1308258.

Inter-observer variability of the histological classification of lupus glomerulonephritis in children.

Oni L, Beresford MW, Witte D, et al.

Lupus 2017; (26(11)):1205-1211 doi:10.1177/0961203317706558.

The value of repeat biopsy in lupus nephritis flares.

Narváez J, Ricse M, Gomà M, et al.

Medicine 2017; (96(24)):e7099 doi:10.1097/MD.0000000000007099.

Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.

Bajema IM, Wilhelmus S, Alpers CE, et al.

Kidney international 2018; (93(4)):789-796 doi:10.1016/j.kint.2017.11.023.

Immunosuppressive treatment for proliferative lupus nephritis.

Tunnicliffe DJ, Palmer SC, Henderson L, et al.

The Cochrane database of systematic reviews 2018; (6()):CD002922 doi:10.1002/14651858.CD002922.pub4.

Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.

Castro M, Ugolini-Lopes M, Borba EF, et al.

Lupus 2018; (27(14)):2215-2219 doi:10.1177/0961203318809883.

Pregnancy outcome in women with active and inactive lupus nephritis: A prospective cohort study.

Attia DH, Mokbel A, Haggag HM, Naeem N

Lupus 2019; (28(7)):806-817 doi:10.1177/0961203319846650.

Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies.

Leatherwood C, Speyer CB, Feldman CH, et al.

Seminars in arthritis and rheumatism 2019; (49(3)):396-404 doi:10.1016/j.semarthrit.2019.06.002.

Podocyte Injury in Lupus Nephritis.

Sakhi H, Moktefi A, Bouachi K, et al.

Journal of clinical medicine 2019; (8(9)) doi:10.3390/jcm8091340.

Syphilis and parvovirus B19 co-infection imitating a lupus nephropathy: A case report.

Jaunin E, Kissling S, Rotman S, et al.

Medicine 2019; (98(36)):e17040 doi:10.1097/MD.0000000000017040.

Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis.

Kudose S, Santoriello D, Bomback AS, et al.

Clinical journal of the American Society of Nephrology : CJASN 2019; (14(11)):1605-1615 doi:10.2215/CJN.01570219.

Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus.

Kandane-Rathnayake R, Kent JR, Louthrenoo W, et al.

Lupus 2019; (28(14)):1669-1677 doi:10.1177/0961203319887799.

Lupus Podocytopathy: An Overview.

Oliva-Damaso N, Payan J, Oliva-Damaso E, et al.

Advances in chronic kidney disease 2019; (26(5)):369-375 doi:10.1053/j.ackd.2019.08.011.

Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.

Kotzen ES, Roy S, Jain K

Advances in chronic kidney disease 2019; (26(5)):376-386 doi:10.1053/j.ackd.2019.08.012.

Membranous Lupus Nephritis: A Clinical Review.

Almaani S, Parikh SV

Advances in chronic kidney disease 2019; (26(5)):393-403 doi:10.1053/j.ackd.2019.08.009.

2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.

Fanouriakis A, Kostopoulou M, Cheema K, et al.

Annals of the rheumatic diseases 2020; (79(6)):713-723 doi:10.1136/annrheumdis-2020-216924.

Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?

Tselios K, Gladman DD, Su J, Urowitz MB

The Journal of rheumatology 2020; (47(9)):1366-1373 doi:10.3899/jrheum.191064.

Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China.

Sun Y, Zhou C, Zhao J, et al.

Lupus 2020; (29(7)):795-803 doi:10.1177/0961203320920715.

Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.

Mok CC, Ho LY, Ying SKY, et al.

Annals of the rheumatic diseases 2020; (79(8)):1070-1076 doi:10.1136/annrheumdis-2020-217178.

Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis.

Moroni G, Gatto M, Tamborini F, et al.

Annals of the rheumatic diseases 2020; (79(8)):1077-1083 doi:10.1136/annrheumdis-2020-216965.

Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression.

Mahajan A, Amelio J, Gairy K, et al.

Lupus 2020; (29(9)):1011-1020 doi:10.1177/0961203320932219.

Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Kostopoulou M, Fanouriakis A, Cheema K, et al.

RMD open 2020; (6(2)) doi:10.1136/rmdopen-2020-001263.

Urinary biomarkers in lupus nephritis.

Aragón CC, Tafúr RA, Suárez-Avellaneda A, et al.

Journal of translational autoimmunity 2020; (3()):100042 doi:10.1016/j.jtauto.2020.100042.

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Furie R, Rovin BH, Houssiau F, et al.

The New England journal of medicine 2020; (383(12)):1117-1128 doi:10.1056/NEJMoa2001180.

Low-Level Proteinuria in Systemic Lupus Erythematosus.

Chedid A, Rossi GM, Peyronel F, et al.

Kidney international reports 2020; (5(12)):2333-2340 doi:10.1016/j.ekir.2020.09.007.

Thrombotic Microangiopathy among Hospitalized Patients with Systemic Lupus Erythematosus in the United States.

Pivovarova AI, Thongprayoon C, Hansrivijit P, et al.

Diseases (Basel, Switzerland) 2020; (9(1)) doi:10.3390/diseases9010003.

Expanding the Role of Complement Therapies: The Case for Lupus Nephritis.

Li NL, Birmingham DJ, Rovin BH

Journal of clinical medicine 2021; (10(4)) doi:10.3390/jcm10040626.

Clinicopathological Pattern of Non-lupus Full House Nephropathy.

Wani AS, Zahir Z, Gupta A, Agrawal V

Indian journal of nephrology 2020; (30(5)):301-306 doi:10.4103/ijn.IJN_91_18.

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Rovin BH, Teng YKO, Ginzler EM, et al.

Lancet (London, England) 2021; (397(10289)):2070-2080 doi:10.1016/S0140-6736(21)00578-X.

A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.

Rovin BH, Furie R, Teng YKO, et al.

Kidney international 2022; (101(2)):403-413 doi:10.1016/j.kint.2021.08.027.

An Interesting Case of Nonlupus Full-House Nephropathy.

Sathi S, Sharma A, Garg AK, et al.

Case reports in nephrology 2021; (2021()):9043003 doi:10.1155/2021/9043003.

The role of anticomplement therapy in lupus nephritis.

Fernandez-Ruiz R, Belmont HM

Translational research : the journal of laboratory and clinical medicine 2022; (245()):1-17 doi:10.1016/j.trsl.2022.02.001.

Rapidly progressive glomerulonephritis in children.

Moorani KN, Aziz M, Amanullah F

Pakistan journal of medical sciences 2022; (38(2)):417-425 doi:10.12669/pjms.38.ICON-2022.5774.

A Review of Lupus Nephritis.

Alforaih N, Whittall-Garcia L, Touma Z

The journal of applied laboratory medicine 2022; (7(6)):1450-1467 doi:10.1093/jalm/jfac036.

Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IV.

Bolognesi MM, Capitoli G, Galimberti S, et al.

Annals of the rheumatic diseases 2022; (81(12)):1704-1711 doi:10.1136/ard-2022-222620.

Tacrolimus use and renal function in pregnancy with lupus nephritis: Analysis of post-marketing surveillance data in Japan.

Suzuki K, Uno S, Wakasugi N

Modern rheumatology 2023; (33(5)):944-952 doi:10.1093/mr/roac094.

Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.

, Silver R, Craigo S, et al.

American journal of obstetrics and gynecology 2023; (228(3)):B41-B60 doi:10.1016/j.ajog.2022.09.001.

Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue.

Kwant LE, Vegting Y, Tsang-A-Sjoe MWP, et al.

Autoimmunity reviews 2022; (21(12)):103211 doi:10.1016/j.autrev.2022.103211.

Development of an instrument to predict proliferative histological class in lupus nephritis based on clinical and laboratory data.

Silaide de Araújo Júnior A, Sato EI, Silva de Souza AW, et al.

Lupus 2023; (32(2)):216-224 doi:10.1177/09612033221143933.

Lupus Membranous Nephropathy.

Ponticelli C, Moroni G, Fornoni A

Glomerular diseases 2021; (1(1)):10-20 doi:10.1159/000512278.

[Lupus nephritis: from diagnosis to treatment].

Weinmann-Menke J

Innere Medizin (Heidelberg, Germany) 2023; (64(3)):225-233 doi:10.1007/s00108-023-01489-y.

Histologic evaluation of activity and chronicity of lupus nephritis and its clinical significance.

Choi SE, Fogo AB, Lim BJ

Kidney research and clinical practice 2023; (42(2)):166-173 doi:10.23876/j.krcp.22.083.

Clinicopathologic characteristics and outcomes of late onset lupus nephritis: a single centre experience.

Sharma H, Kaul A, Mohakuda SS, et al.

Rheumatology international 2023; (43(10)):1849-1858 doi:10.1007/s00296-023-05357-8.

Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis.

Tsai CY, Li KJ, Shen CY, et al.

International journal of molecular sciences 2023; (24(12)) doi:10.3390/ijms241210066.

Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention.

Banos A, Bertsias G

Current rheumatology reports 2023; (25(10)):183-191 doi:10.1007/s11926-023-01109-6.

Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.

Saxena A, Ginzler EM, Gibson K, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2024; (76(1)):59-67 doi:10.1002/art.42657.

Etiology and Outcomes of Rapidly Progressive Glomerulonephritis in Children: A Retrospective Cohort Study.

Deepthi B, Krishnamurthy S, Ganesh RN, et al.

Indian pediatrics 2023; (60(10)):816-821.

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Fanouriakis A, Kostopoulou M, Andersen J, et al.

Annals of the rheumatic diseases 2024; (83(1)):15-29 doi:10.1136/ard-2023-224762.

Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis?

Wagner BR, Rao PS

Current opinion in rheumatology 2024; (36(3)):163-168 doi:10.1097/BOR.0000000000001002.

II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.

Reis-Neto ETD, Seguro LPC, Sato EI, et al.

Advances in rheumatology (London, England) 2024; (64(1)):48 doi:10.1186/s42358-024-00386-8.

A Comprehensive and Practical Approach to the Management of Lupus Nephritis in the Current Era.

Wiegley N, Arora S, Norouzi S, Rovin B

Advances in kidney disease and health 2024; (31(3)):234-245 doi:10.1053/j.akdh.2023.11.003.

Lupus nephritis-related chronic kidney disease.

Lichtnekert J, Anders HJ

Nature reviews. Rheumatology 2024; (20(11)):699-711 doi:10.1038/s41584-024-01158-w.

Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS.

Dall'Era M, Kalunian K, Solomons N, et al.

Lupus science & medicine 2024; (11(2)) doi:10.1136/lupus-2024-001319.

Analysis of the Sensitivity and Specificity of Histopathological Findings for Diagnosing Lupus Nephritis.

da Luz Neto ER, Tavares MB, de Melo AGJT, et al.

Diagnostics (Basel, Switzerland) 2024; (14(23)) doi:10.3390/diagnostics14232681.

The Role of Podocytes in Lupus Pathology.

Maeda K, Abdi R, Tsokos GC

Current rheumatology reports 2024; (27(1)):10 doi:10.1007/s11926-024-01175-4.

The 2024 APLAR Consensus on the Management of Lupus Nephritis.

Mok CC, So H, Hamijoyo L, et al.

International journal of rheumatic diseases 2025; (28(1)):e70021 doi:10.1111/1756-185X.70021.

Lupus nephritis: Biomarkers.

Dobrowolski C, Lao SM, Kharouf F, et al.

Advances in clinical chemistry 2025; (124()):87-122 doi:10.1016/bs.acc.2024.10.002.

New Insights on Childhood Lupus Nephritis.

Marchi-Silva R, De Aquino BM, Londe AC, et al.

International journal of nephrology and renovascular disease 2025; (18()):1-12 doi:10.2147/IJNRD.S405789.

Challenges in the care of patients with systemic lupus erythematosus and lupus nephritis in Latin America.

Elera-Fitzcarrald C, Alarcón GS, Ugarte-Gil MF

Expert opinion on pharmacotherapy 2025; (26(4)):447-455 doi:10.1080/14656566.2025.2464913.

Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunity.

Kronbichler A

Seminars in arthritis and rheumatism 2025; (72S()):152663 doi:10.1016/j.semarthrit.2025.152663.

Diffuse Alveolar Hemorrhage as the First Presentation of Systemic Lupus Erythematosus: A Case Report.

Later S, Abdelbagi M, Zaaroura A, et al.

The American journal of case reports 2025; (26()):e947096 doi:10.12659/AJCR.947096.

Lupus nephritis.

Parodis I, Rovin BH, Tektonidou MG, et al.

Nature reviews. Disease primers 2025; (11(1)):69 doi:10.1038/s41572-025-00653-y.

Current treatment of lupus nephritis: an overview of the new guidelines.

Sales GTM, Macedo NJ, Reis Neto ETD, Kirsztajn GM

Jornal brasileiro de nefrologia 2025; (47(4)):e20250092 doi:10.1590/2175-8239-JBN-2025-0092en.

Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review.

Vrabie A, Obrișcă B, Sorohan BM, Ismail G

Life (Basel, Switzerland) 2025; (15(10)) doi:10.3390/life15101497.

Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments.

Praga M, Caravaca-Fontán F, Cavero T, et al.

Kidney international 2026; (109(2)):297-308 doi:10.1016/j.kint.2025.09.033.

Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial.

Vajgel G, Júnior BMDS, Filho CRSM, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; (41(7)):1253-1261 doi:10.1093/ndt/gfaf257.

Balancing stringency and feasibility: comparative value of disease-activity measures to predict pregnancy outcomes in systemic lupus erythematosus.

Chen Y, Lin S, Wang M, et al.

Lupus science & medicine 2026; (13(1)) doi:10.1136/lupus-2025-001793.

Beyond glomeruli in lupus nephritis: Impact of tubulointerstitial inflammation and interstitial fibrosis/tubular atrophy on renal function decline - A systematic review and meta-analysis.

Donato KO, Donato AO, Gonçalves LF, et al.

Lupus 2026; (35(7)):709-721 doi:10.1177/09612033261437467.

Diffuse alveolar hemorrhage in rheumatic diseases: Clinical features, diagnosis, and management.

Dutta N, Patil H, Gopinath V, et al.

Rheumatology and immunology research 2026; (7(1)):1-13 doi:10.1515/rir-2026-0008.

Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis.

Zhang S, Magder L, Goldman D, et al.

Arthritis care & research 2026; doi:10.1002/acr.80070.

New age of Lupus Nephritis: Updates in guidelines, biomarkers, and therapies.

Ibrahim M, He E, Tran D, et al.

Best practice & research. Clinical rheumatology 2026; (40(3)):102153 doi:10.1016/j.berh.2026.102153.

Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024.

Xipell M, Iraola M, Mirioglu S, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; doi:10.1093/ndt/gfag106.

Male infertility in lupus nephritis: Clinical implications and management strategies.

Elahi T, Ahmed S, Mubarak M

Lupus 2026; (35(10)):1003-1012 doi:10.1177/09612033261454513.

Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy.

Golubović S, Živković S, Veselinov V, et al.

Lupus 2026; (35(12)):1217-1226 doi:10.1177/09612033261469025.

A Rare Diagnostic Dilemma of P-ANCA/MPO Positive Crescentic Glomerulonephritis in an Immunosuppressed Lupus Patient.

Elrefy O, Carpenter S, Saini M, et al.

Case reports in nephrology 2026; (2026()):1850355 doi:10.1155/crin/1850355.

Decoding Lupus Diagnosis, Pathogenesis and Therapy: From Systemic Autoimmunity to Renal Damage.

Netti GS, Troise D, Infante B, et al.

Diagnostics (Basel, Switzerland) 2026; (16(14)) doi:10.3390/diagnostics16142170.

Severe Class III Lupus Nephritis With Concurrent Thrombotic Microangiopathy and Suspected Atypical Hemolytic Uremic Syndrome Requiring Complement Blockade: A Complex Multisystem Presentation.

Pokharel N, Alvi A, Best A

Cureus 2026; (18(6)):e111765 doi:10.7759/cureus.111765.

Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.

Rossi GM, Pala C, Fontana F, et al.

Medicina (Kaunas, Lithuania) 2026; (62(9)) doi:10.3390/medicina62091653.